275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY, CA
Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism
Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
FY 2025
Q3
Q2
Q1
S-3ASR
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Correspondence
Submission Upload